TIGIT and breast cancer: TIGIT blockade using a monoclonal antibody resulted in delayed tumor growth, reduced metastasis, improved survival, and the reversed exhaustion of tumor-infiltrating NK cells in preclinical models of colon cancer, breast cancer, and fibrosarcoma [65].